Phase I/II study with GEM/TS-1 combination for metastatic breast cancer (KSCOG BC-03)
Phase 1
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000008859
- Lead Sponsor
- Kurume University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Non-invasive cancer or micro-invasive cancer 2. taboo to use Gemcitabine or TS-1 3. male breast cancer 4.pregnant or nursing women or who suspected pregnant 5.with active double cancer 6.with severe complications 7.had a previous cardiac dysfunction or having cardiac dysfunction 8.uncontrolled edema 9.had a previous serious medical illness or allergy 10.doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method